Artificial intelligence in thyroid nodule risk stratification and early detection: A narrative review of current evidence and clinical implications
TL;DR
Current AI applications in thyroid nodule risk stratification are examined, performance metrics across different modalities are analyzed, clinical implications for early detection and optimized management are discussed, and future directions are explored, including multimodal integration and real-time clinical decision support systems.
Abstract
Thyroid nodules are increasingly detected incidentally, with prevalence rates of 19%–68% in ultrasound studies, yet only 7%–15% harbor malignancy. Traditional risk stratification systems demonstrate significant inter-observer variability and modest diagnostic accuracy. Artificial intelligence (AI) and machine learning technologies have emerged as powerful tools for enhancing thyroid nodule evaluation and enabling more precise risk-based clinical management. Deep learning algorithms, particularly convolutional neural networks, demonstrate diagnostic accuracy of 83%–97% in differentiating benign from malignant thyroid nodules on ultrasound, often matching or exceeding expert radiologists. AI systems analyzing cytopathology images achieve a sensitivity of 87%–99% and specificity of 71%–97% in predicting malignancy from fine-needle aspiration specimens. Integration of radiomics features, molecular markers, and clinical data through machine learning models enables personalized risk prediction with area under the curve values exceeding 0.90. These technologies promise to reduce unnecessary biopsies and surgeries, minimize patient anxiety, and optimize resource utilization. However, implementation challenges include limited external validation, algorithmic transparency concerns, regulatory considerations, and the need for prospective clinical trials. This narrative review examines current AI applications in thyroid nodule risk stratification, analyzes performance metrics across different modalities, discusses clinical implications for early detection and optimized management, and explores future directions, including multimodal integration and real-time clinical decision support systems. As AI technology matures, its role in transforming thyroid nodule evaluation from population-based screening to personalized risk-stratified surveillance appears increasingly promising.